Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily in the evening) over 48 weeks, compared to placebo, in children (6 to 11 years old) with moderate persistent asthma.
Epistemonikos ID: fca6e4db9e80fcfdff5a70fb852e0f84df0be695
First added on: May 11, 2024